LENZ Therapeutics, Inc. LENZ

3.92 0.20 5.38% as of 25 Sep
Market cap
$117.4M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — — — — — — 0.00
P/S ratio
— — — — — — — 0.00
P/FCF ratio
— — — — — — — 0.00
P/Operating CF
— — — — — — — (13.96)
P/B ratio
— — — — — — — 1.62
Price to Tangible BV
— — — — — — — 1.62
EV/Sales
— — — — — — — 0.00
EV/EBITDA
— — — — — — — 0.00
EV/Operating CF
— — — — — — — (2.49)
EV/FCF
— — — — — — — (2.46)
Quick Ratio
— 0.00 0.62 31.04 20.57 3.55 20.10 13.81
Current Ratio
— 0.00 0.66 31.44 21.11 3.63 20.36 14.23
Net Debt/EBITDA
— (75.83) 1.48 6.31 2.52 0.90 3.57 3.22
Debt/Assets
0.00% 36,750.00% 0.00% 0.00% 1.26% 0.00% 0.00% 0.00%
Debt/Equity
— (0.99) 0.00 0.00 0.01 0.00 0.00 0.00
Asset Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.07
Operating CF/Net income
— 0.17 0.13 0.75 0.87 0.86 1.19 0.84
Capex/Depreciation
— — (12.77) (7.82) (8.77) 0.03 (8.07) (2.88)
Interest Coverage
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— 0.32% 202.21% (44.41%) (29.71%) (68.74%) (89.37%) (33.63%)
ROA
— (3,633.33%) (605.88%) (33.33%) (27.92%) (35.67%) (34.84%) (31.52%)
ROIC
— 0.00% 0.00% (534.02%) (205.64%) 0.00% 0.00% 0.00%
Return on Tangible Assets
— 4.91% 720.93% (18.81%) (35.46%) (143.42%) (24.62%) (29.18%)
Average Days of Receivables
— — — — — — — 6.29
Research and Development Expense of Revenue
— — 0.00% 0.00% 0.00% 0.00% 0.00% 97.81%
Selling, General and Administrative Expense of Revenue
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 477.46%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— — 0.00% 0.00% 0.00% 0.00% 0.00% 65.73%
Graham Net Nets
— — — — — — — 0.61
Graham Number
— — — — — — — 0.00
Earnings Yield
— — — — — — — (17.56%)
Free Cash Flow Yield
— — — — — — — (15.18%)
Revenue per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.66
Operating CF per Share
— 0.00 (26.72) (12.79) (11.22) (30.82) (2.79) (2.40)
Capex per Share
— 0.00 (4.73) (1.39) (0.84) (0.02) (0.02) (0.03)
Free Cash Flow per Share
— 0.00 (31.45) (14.18) (12.06) (30.84) (2.81) (2.43)
Cash per Share
— 0.00 60.71 91.22 34.21 33.59 9.83 10.15
Shareholders Equity per Share
— 0.00 (200.39) 92.93 37.79 (47.33) 9.59 9.87
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— 0.00 (200.39) 92.93 37.79 (47.33) 9.59 9.87
Free Cash Flow
— (0.02) (10.27) (58.59) (94.57) (60.41) (59.86) (70.00)
Working Capital
— (2.22) (10.94) 369.59 262.32 48.73 201.51 280.23
Capital Expenditures
— — (1.54) (5.74) (6.59) (0.03) (0.47) (0.83)
Net Current Asset Value
— (2.22) (66.87) 363.80 249.75 (95.84) 200.70 279.88
EV/EBIT
— — — — — — — 0.00
Capex to Sales
— — 0.00 0.00 0.00 0.00 0.00 0.04
Net Profit Margin
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (430.25%)
Price to Operating Income
— — — — — — — 0.00
Other line items
Depreciation/Fixed assets
— — 0.08 0.11 0.03 (19.30) 0.09 0.24
Cash ROIC
— 271.43% 22.33% (7.80%) (19.45%) 224.51% (14.53%) (12.20%)
Accounts Receivable Turnover
— — — — — — — 0.00
Accounts Payable Turnover
— — 0.08 0.48 3.30 0.00 0.00 0.10
Inventory Turnover
— — 0.00 0.00 0.00 — — 0.00
Average Days of Payables
— — 1,900.41 1,219.82 114.06 0.00 0.00 3,638.65
Days of Inventory on Hand
— — 0.00 0.00 0.00 — — 2,563.73
Average Payables
— — 1.54 1.54 2.53 4.16 4.98 4.21
Average Assets
— 0.00 11.29 212.28 361.94 196.14 142.84 260.59
Average Common Equity
— (33.81) (33.81) 159.32 340.17 101.79 55.69 244.21

Fold the line items

Columns are period end dates